Tearsheet
MNPR Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About MNPR Interactive Breakdown Better Bets vs. MNPR Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Trade Sentinel Investor Videos Industry Resource Links External Quote Links

Monopar Therapeutics (MNPR)

Market Price (6/26/2026): $87.68 | Market Cap: $748.4 MilSector: Health Care | Industry: Biotechnology

Monopar Therapeutics (MNPR)

Market Price (6/26/2026): $87.68
Market Cap: $748.4 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18%

Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more.

Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.54, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 18%

Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -19 Mil

Stock price has recently run up significantly
12M Rtn12 month market price return is 175%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.4%

Key risks
MNPR key risks include [1] a history of clinical trial failure with its Validive program and [2] significant competitive threats to its lead asset, Show more.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -18%
1 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more.
2 Meaningful short interest
Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 12.54, Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 18%
3 Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
4 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -19 Mil
5 Stock price has recently run up significantly
12M Rtn12 month market price return is 175%
6 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -6.4%
7 Key risks
MNPR key risks include [1] a history of clinical trial failure with its Validive program and [2] significant competitive threats to its lead asset, Show more.

MNPR in ETFs

Weight = MNPR's share of each fund

VTI0.00%
ITOT0.00%
IWM0.01%
IWO0.02%
VTWO0.01%

Valuation & Metrics

FYE: 12/31MNPR [1]S&P 500 [2]
REVENUE GROWTH
LTM Revenue [3]$0.0 Mil—
FY 2026 Sales$0.4 Mil—
FY 2027 Sales$15.4 Mil—
FY 2026 Sales Growth——
FY 2027 Sales Growth3,751.2%8.2%
EARNINGS
LTM Net Income (GAAP) [3]$-15.0 Mil—
FY 2026 Net Income (Non-GAAP)$-20.2 Mil—
FY 2027 Net Income (Non-GAAP)$-36.2 Mil—
FY 2027 Net Income Growth—15.6%
FY 2026 EPS (Non-GAAP)$-2.77—
FY 2027 EPS (Non-GAAP)$-3.51—
FY 2027 EPS Growth——
VALUATION
FY 2026 P/S1,871.03.3
FY 2027 P/S48.6—
FY 2026 P/E—20.3
FY 2027 P/E——

[1] MNPR forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
[2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 6/30/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
[3] LTM = reported trailing-twelve-month actuals (GAAP).
null

AI Analysis | Feedback

MetricValueDateSource
Active Clinical Trials510282025Link
Lead Product Candidate in Phase 2b/3Validive3092022Link
Product Candidate in Phase 1bCamsirubicin7112023Link
Product Candidate in Phase 1MNPR-101-Zr6112025Link
Product Candidate in Phase 1aMNPR-101-Lu6112025Link
Total Patent Families269042025Link
Granted Patents179042025Link
Pending Patents99042025Link
Number of Employees1611072025Link
Number of Collaborations46112024Link

Price Chart

null
Upcoming
8/11/2026Earnings ReleaseRev: -
EPS: -

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Updated on 6/24/2026

Monopar Therapeutics (MNPR) stock has gained about 60% since 2/28/2026 because of the following key factors:

1. Positive Phase 3 Clinical Trial Results for ALXN1840. Monopar Therapeutics presented new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline) in April 2026, demonstrating significantly greater neurologic benefit versus standard of care in Wilson disease patients with neurologic symptoms. Specifically, only 9% of patients treated with ALXN1840 experienced clinically meaningful neurologic worsening at Week 48, compared to 25% of patients on standard of care (p=0.038).

2. Advancing ALXN1840 Towards Commercialization with Robust Phase 2 Data. Further positive Phase 2 data for ALXN1840 was presented in May 2026, showing liver disease stabilization and significant neurologic improvement in treatment-experienced Wilson disease patients, as evidenced by improvements in the Unified Wilson Disease Rating Scale (UWDRS) Part III and Clinical Global Impressions (CGI) scale (p < 0.05 vs. baseline). The company affirmed it remains on track to submit the New Drug Application (NDA) for ALXN1840 to the U.S. Food and Drug Administration (FDA) in mid-2026 and appointed a Chief Commercial and Strategy Officer in March 2026 to lead commercial readiness activities.

Show more
Updated on 6/24/2026

Monopar Therapeutics (MNPR) stock has gained about 60% since 2/28/2026 because of the following key factors:

1. Positive Phase 3 Clinical Trial Results for ALXN1840. Monopar Therapeutics presented new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline) in April 2026, demonstrating significantly greater neurologic benefit versus standard of care in Wilson disease patients with neurologic symptoms. Specifically, only 9% of patients treated with ALXN1840 experienced clinically meaningful neurologic worsening at Week 48, compared to 25% of patients on standard of care (p=0.038).

2. Advancing ALXN1840 Towards Commercialization with Robust Phase 2 Data. Further positive Phase 2 data for ALXN1840 was presented in May 2026, showing liver disease stabilization and significant neurologic improvement in treatment-experienced Wilson disease patients, as evidenced by improvements in the Unified Wilson Disease Rating Scale (UWDRS) Part III and Clinical Global Impressions (CGI) scale (p < 0.05 vs. baseline). The company affirmed it remains on track to submit the New Drug Application (NDA) for ALXN1840 to the U.S. Food and Drug Administration (FDA) in mid-2026 and appointed a Chief Commercial and Strategy Officer in March 2026 to lead commercial readiness activities.

3. Strong Financial Position. Monopar reported cash, cash equivalents, and investments of $137.5 million as of the close of fiscal Q1 2026 (March 31, 2026). This capital is projected to support operations through at least December 31, 2027, providing financial stability for ongoing regulatory and development activities, including for ALXN1840 and MNPR-101 programs.

4. Q1 2026 Earnings Beat. For fiscal Q1 2026, Monopar Therapeutics reported a net loss of $3.9 million, or $0.46 per share, which favorably beat the consensus analyst estimate of a net loss of $0.87 per share by $0.41.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 59.9% change in MNPR stock from 2/28/2026 to 6/25/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
(LTM values as of)22820266252026Change
Stock Price ($)54.8087.6359.9%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)79-16.5%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

2/28/2026 to 6/25/2026
ReturnCorrelation
MNPR59.9% 
Market (SPY)7.3%25.2%
Sector (XLV)-2.5%20.2%

Fundamental Drivers

The 1.7% change in MNPR stock from 11/30/2025 to 6/25/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
(LTM values as of)113020256252026Change
Stock Price ($)86.1887.631.7%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)79-16.5%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

11/30/2025 to 6/25/2026
ReturnCorrelation
MNPR1.7% 
Market (SPY)8.1%23.5%
Sector (XLV)-0.5%17.7%

Fundamental Drivers

The 176.2% change in MNPR stock from 5/31/2025 to 6/25/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
(LTM values as of)53120256252026Change
Stock Price ($)31.7387.63176.2%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)79-18.1%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

5/31/2025 to 6/25/2026
ReturnCorrelation
MNPR176.2% 
Market (SPY)26.0%22.5%
Sector (XLV)19.4%13.7%

Fundamental Drivers

The 1692.0% change in MNPR stock from 5/31/2023 to 6/25/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
(LTM values as of)53120236252026Change
Stock Price ($)4.8987.631692.0%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)39-69.3%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

5/31/2023 to 6/25/2026
ReturnCorrelation
MNPR1692.0% 
Market (SPY)82.6%6.5%
Sector (XLV)28.0%1.1%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
MNPR Return-48%-26%-86%1193%197%36%191%
Peers Return43%-20%3%78%-33%-13%23%
S&P 500 Return27%-19%24%23%16%7%96%

Monthly Win Rates [3]
MNPR Win Rate17%33%17%42%67%33% 
Peers Win Rate46%50%46%58%75%43% 
S&P 500 Win Rate75%42%67%75%67%50% 

Max Drawdowns [4]
MNPR Max Drawdown-70%-60%-92%-67%-46%-33% 
Peers Max Drawdown-41%-46%-34%-26%-59%-39% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 

[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ATYR, AVLN, CNXU, COAG.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/25/2026 (YTD)

How Low Can It Go

EventMNPRS&P 500
2025 US Tariff Shock
  % Loss-37.0%-18.8%
  % Gain to Breakeven58.8%23.1%
  Time to Breakeven10 days79 days
2024 Yen Carry Trade Unwind
  % Loss-37.2%-7.8%
  % Gain to Breakeven59.3%8.5%
  Time to Breakeven34 days18 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-60.4%-9.5%
  % Gain to Breakeven152.7%10.5%
  Time to Breakeven94 days24 days
2023 SVB Regional Banking Crisis
  % Loss-78.7%-6.7%
  % Gain to Breakeven369.2%7.1%
  Time to Breakeven472 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-57.1%-24.5%
  % Gain to Breakeven132.9%32.4%
  Time to Breakeven46 days427 days
2020 COVID-19 Crash
  % Loss-54.6%-33.7%
  % Gain to Breakeven120.4%50.9%
  Time to Breakeven2010 days140 days

Compare to VRTX, ATYR, AVLN, CNXU, COAG

In The Past

Monopar Therapeutics's stock fell -37.0% during the 2025 US Tariff Shock. Such a loss loss requires a 58.8% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventMNPRS&P 500
2025 US Tariff Shock
  % Loss-37.0%-18.8%
  % Gain to Breakeven58.8%23.1%
  Time to Breakeven10 days79 days
2024 Yen Carry Trade Unwind
  % Loss-37.2%-7.8%
  % Gain to Breakeven59.3%8.5%
  Time to Breakeven34 days18 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-60.4%-9.5%
  % Gain to Breakeven152.7%10.5%
  Time to Breakeven94 days24 days
2023 SVB Regional Banking Crisis
  % Loss-78.7%-6.7%
  % Gain to Breakeven369.2%7.1%
  Time to Breakeven472 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-57.1%-24.5%
  % Gain to Breakeven132.9%32.4%
  Time to Breakeven46 days427 days
2020 COVID-19 Crash
  % Loss-54.6%-33.7%
  % Gain to Breakeven120.4%50.9%
  Time to Breakeven2010 days140 days

Compare to VRTX, ATYR, AVLN, CNXU, COAG

In The Past

Monopar Therapeutics's stock fell -37.0% during the 2025 US Tariff Shock. Such a loss loss requires a 58.8% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Monopar Therapeutics (MNPR)

Monopar Therapeutics Inc. (MNPR) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for the treatment of cancer. Its most advanced product candidate is Validive, a clonidine hydrochloride mucobuccal tablet currently in Phase 2b/3 clinical trials. Validive aims to prevent severe oral mucositis, a debilitating side effect, in patients with oropharyngeal cancer undergoing chemoradiotherapy.

The company's pipeline extends to several other promising drug candidates. Camsirubicin, an analog of doxorubicin, is in Phase 1b development for advanced soft tissue sarcoma. Monopar is also developing MNPR-101, a targeted antibody for various cancers, and MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101, which targets both cancer and severe COVID-19. Furthermore, MNPR-202 is an analog of camsirubicin being developed to potentially treat cancers resistant to current therapies. Monopar Therapeutics primarily serves the oncology market, addressing critical unmet needs for cancer patients, and is also exploring an application in severe COVID-19.

AI Analysis | Feedback

  • It's like an early-stage Genentech, but specialized in developing several new cancer and supportive care therapies.
  • Think of it as a small, independent version of the oncology R&D division of a major pharmaceutical company like Pfizer or Merck.

AI Analysis | Feedback

  • Validive: A clonidine hydrochloride mucobuccal tablet in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients.
  • Camsirubicin: An analog of doxorubicin in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma.
  • MNPR-101: A urokinase plasminogen activator receptor targeted antibody developed for the treatment of various cancers.
  • MNPR-101 RIT: A radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19.
  • MNPR-202: An analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.

AI Analysis | Feedback

As a clinical-stage biopharmaceutical company, Monopar Therapeutics Inc. (MNPR) is engaged in the research and development of therapeutic product candidates. Its lead candidates are currently in Phase 1b or Phase 2b/3 clinical trials. Therefore, Monopar Therapeutics does not currently have major customers for its therapeutic products, as these products are still under development and have not yet been approved for commercial sale to other companies or individual patients.

AI Analysis | Feedback

  • NorthStar Medical Radioisotopes, LLC

AI Analysis | Feedback

Chandler D. Robinson, MD MBA MSc – Co-Founder, Chief Executive Officer and Board Member

Dr. Robinson co-founded Monopar Therapeutics and has served as its CEO since its inception in 2014. He previously co-founded and was CEO of Tactic Pharma, where he led the successful sale of its lead compound. He was also a co-founder and board member of Wilson Therapeutics, which was acquired by Alexion (now AstraZeneca). His prior experiences include working in the Nexavar marketing division at Onyx Pharmaceuticals, co-managing a healthcare clinic, and working at Bear Stearns investment bank. Dr. Robinson founded and presides over an undergraduate research-focused non-profit. A compound he researched as an undergraduate at Northwestern University, and published on in Science, completed a Phase III clinical trial for Wilson Disease and is now being advanced to an NDA filing at Monopar.

Quan Vu – Chief Financial Officer

Mr. Vu was appointed Chief Financial Officer of Monopar Therapeutics effective March 3, 2025. He brings over 20 years of experience in corporate and financial strategy, investment banking, and public company management. Mr. Vu has served as a Venture Partner at ZhongMei Capital, an investment firm focused on early-stage biopharmaceutical companies. His previous roles include Chief Financial Officer and Chief Business Officer at Ocugen, Inc., and Chief Operating Officer and Chief Business Officer for 180 Life Sciences Corp. He also provided consulting services through his firm, Melius BioPharma Consulting, and held leadership positions at Opiant Pharmaceuticals, Inc., Impax Laboratories, Inc., Elevance Health, Inc. (formerly Anthem, Inc.), and Amgen, Inc. His early career involved work in healthcare corporate finance and mergers & acquisitions at Morgan Stanley and Goldman Sachs.

Andrew Cittadine, MBA – Chief Operating Officer

Mr. Cittadine provides leadership and oversight of global operations and business development strategy, leveraging his background in building and selling healthcare businesses. He received his BA, BS, and MS from Stanford and an MBA from Northwestern's Kellogg School of Management.

Andrew P. Mazar, PhD – Co-Founder & EVP, Research & Development

Dr. Mazar is a co-founder of Monopar Therapeutics.

Christopher M. Starr – Co-Founder and Executive Chairman of the Board

Mr. Starr is a co-founder of Monopar Therapeutics and serves as the Executive Chairman of the Board.

AI Analysis | Feedback

Key Risks to Monopar Therapeutics (MNPR)

  1. Clinical Trial Failure and Inability to Obtain Regulatory Approval: As a clinical-stage biopharmaceutical company, Monopar Therapeutics' business prospects are fundamentally tied to the successful outcome of its ongoing and future clinical trials for product candidates such as Validive (in Phase 2b/3), Camsirubicin (in Phase 1b), MNPR-101, MNPR-101 RIT, and MNPR-202. Biopharmaceutical drug development inherently involves a high risk of failure at various stages of clinical trials due to lack of efficacy, safety concerns, or unforeseen side effects. Furthermore, even with successful trial data, there is no guarantee that regulatory bodies, such as the FDA, will grant marketing approval. The failure of any of its lead product candidates to successfully complete trials or receive regulatory approval would prevent Monopar from commercializing its therapies and generating revenue, which would significantly impact its viability.
  2. Dependence on External Funding: Monopar Therapeutics currently has no revenue-generating commercialized products and is engaged in costly research and development activities, particularly advanced clinical trials. The company's continued operations and its ability to advance its pipeline are heavily reliant on its capacity to raise substantial additional capital through equity offerings, debt financing, or strategic partnerships. Failure to secure adequate and timely funding could lead to delays, suspension, or termination of its critical development programs, thereby threatening the company's long-term sustainability.
  3. Competition and Market Acceptance: Should Monopar's product candidates successfully complete clinical trials and receive regulatory approval, they will enter highly competitive markets for the treatment of cancer and severe COVID-19. They will face competition from existing therapies, including established drugs and generic alternatives, as well as new treatments being developed by larger, more established biopharmaceutical companies. The ability to achieve significant market acceptance, establish competitive pricing, and secure favorable reimbursement will be crucial for commercial success, and there is a risk that Monopar's products may not achieve sufficient market share or pricing power to generate substantial revenue.

AI Analysis | Feedback

null

AI Analysis | Feedback

Monopar Therapeutics (MNPR) operates in several distinct therapeutic areas with the following addressable market sizes:

  • Validive (for chemoradiotherapy induced severe oral mucositis): The global market for chemotherapy-induced oral mucositis is anticipated to grow from USD 1.35 billion in 2025 to USD 2.20 billion in 2035, exhibiting a compound annual growth rate (CAGR) of 5.3%.
  • Camsirubicin (for advanced soft tissue sarcoma): The soft tissue sarcoma market across the top 7 major markets (United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan) was valued at USD 2.8 billion in 2024 and is projected to reach USD 5.0 billion by 2035, growing at a CAGR of 5.10%. The global soft tissue sarcoma treatment market size was valued at USD 1,455.12 million in 2024 and is projected to grow to USD 3,910.15 million by 2034, with a CAGR of 10.4%.
  • MNPR-101 (urokinase plasminogen activator receptor targeted antibody for various cancers): The global urokinase market size was valued at USD 1.8 billion in 2023 and is projected to reach USD 3.1 billion by 2033, growing at a CAGR of 5.7%. Urokinase-type plasminogen activator receptor (uPAR) is identified as an attractive target for cancer therapies. The global market for Urokinase was estimated at US$1.8 billion in 2024 and is expected to reach US$2.4 billion by 2030, with a CAGR of 4.6%.
  • MNPR-101 RIT (radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer): The global radioimmunotherapy market size was estimated at USD 2.68 billion in 2024 and is predicted to surpass approximately USD 12.70 billion by 2034, growing at a CAGR of 16.83%. North America accounts for approximately 45% of the global share.
  • MNPR-202 (analog of camsirubicin to potentially treat doxorubicin- and camsirubicin-resistant cancers): The global doxorubicin market was valued at USD 1.8 billion in 2024 and is projected to reach USD 2.6 billion by 2032, with a CAGR of 4.7%. Another estimate indicates the global doxorubicin market size was valued at USD 1.06 billion in 2024 and is projected to grow from USD 1.14 billion in 2025 to reach USD 1.76 billion by 2033, exhibiting a CAGR of 5.6%.

AI Analysis | Feedback

For Monopar Therapeutics (MNPR), the expected drivers of future revenue growth over the next 2-3 years are primarily centered on the progression and potential commercialization of its refocused pipeline, particularly its radiopharmaceutical programs and the recently acquired asset for Wilson Disease.

  1. Potential FDA Approval and Commercialization of ALXN1840 for Wilson Disease: Monopar Therapeutics assumed full responsibility for the investigational new drug (IND) application for ALXN1840, a treatment for Wilson Disease, from Alexion Pharmaceuticals in June 2025. The company is preparing to submit a New Drug Application (NDA) to the FDA in early 2026. Successful regulatory approval and subsequent commercial launch of ALXN1840 represent a significant near-term revenue growth driver.
  2. Advancement and Potential Commercialization of MNPR-101-Lu (Therapeutic Radiopharmaceutical): Monopar's therapeutic radiopharmaceutical, MNPR-101-Lu, targets uPAR-expressing advanced or metastatic solid tumors. The FDA cleared its IND application in September 2025, allowing for a Phase 1 dosimetry and dose-escalation trial. Clinical trials are currently active and enrolling patients in Australia, with an Expanded Access Program also active in the U.S. Positive clinical data and progression to later stages could lead to partnerships or eventual market entry within the 2-3 year timeframe or shortly thereafter, generating revenue.
  3. Progression and Potential Commercialization of MNPR-101-Zr (Imaging Radiopharmaceutical): MNPR-101-Zr is an imaging agent designed to target uPAR in advanced cancer patients. This asset is currently in a first-in-human Phase 1 imaging and dosimetry clinical trial. Successful development and potential approval of this imaging agent could provide revenue through its use in cancer diagnosis and patient selection for uPAR-targeted therapies.
  4. Strategic Partnerships and Collaborations: As a clinical-stage biopharmaceutical company, Monopar's revenue growth can be significantly driven by securing and expanding strategic partnerships. Collaborations, similar to its ongoing relationship with NorthStar Medical Radioisotopes for radiopharmaceuticals, can provide non-dilutive funding, upfront payments, and milestone payments upon achieving certain development or regulatory objectives. Such partnerships could support the continued development and eventual commercialization of its pipeline assets.

AI Analysis | Feedback

Capital Allocation Decisions for Monopar Therapeutics (MNPR) Over the Last 3-5 Years

Share Repurchases

  • In September 2025, Monopar Therapeutics repurchased 550,229 shares of its common stock from Tactic Pharma for $35 million, at a price of $63.6098 per share, using proceeds from a public offering.

Share Issuance

  • In September 2025, Monopar completed an underwritten public offering of 1,034,433 shares of common stock and pre-funded warrants to purchase 960,542 shares of common stock, generating approximately $126.9 million in aggregate net proceeds before underwriting discounts and offering expenses.
  • In October 2024, the company raised approximately $19.2 million in gross proceeds through a public offering of common stock, priced at $16.25 per share.
  • During the nine months ended September 30, 2024, Monopar issued 509,061 shares of common stock under a "Capital on Demand Sales Agreement," raising $3,194,310.

Inbound Investments

  • In October 2024, Monopar in-licensed ALXN1840 for Wilson disease from Alexion, AstraZeneca Rare Disease, a deal that included a $4 million upfront cash payment and the issuance of 387,329 shares of common stock to Alexion.
  • Monopar strengthened its financial position by raising over $55 million through various public offerings and private placements during the fourth quarter of 2024 and early 2025.

Capital Expenditures

  • Research and development (R&D) expenses for the year ended December 31, 2023, were $5.6 million, a decrease from $7.6 million in 2022. This reduction was primarily due to lower costs associated with the Validive and camsirubicin clinical trials, partially offset by increased activity in the MNPR-101 radiopharmaceutical program.
  • R&D expenses in the second quarter of 2025 increased to $1,730,000 from $1,130,978 in the second quarter of 2024, mainly driven by higher R&D personnel expenses, including stock-based compensation.
  • The company plans to continue investing in its radiopharmaceutical pipeline, including ongoing clinical trials for MNPR-101-Zr and MNPR-101-Lu, and advancing the preclinical MNPR-101-Ac program, with current funds anticipated to support operations at least through December 31, 2027.

Latest Trefis Analyses

Recent Active Movers

Top Gainers

TickerCompanyCategory1W RtnYTD Rtn
XBIState Street SPDR S&P Biotech ETFEquity8.8%24.3%
IBBiShares Biotechnology ETFEquity5.9%8.9%
KREState Street SPDR S&P Regional Bankin...Equity5.1%16.0%
IJTiShares S&P Small-Cap 600 Growth ETFEquity4.6%24.3%
SLYGState Street SPDR S&P 600 Small Cap G...Equity4.3%24.4%
VHTVanguard Health Care ETFEquity4.3%2.5%
SOXXiShares Semiconductor ETFEquity4.2%107.7%
VLUEiShares MSCI USA Value Factor ETFEquity4.2%50.3%
IYTiShares U.S. Transportation ETFEquity4.0%16.7%
IJRiShares Core S&P Small-Cap ETFEquity4.0%21.9%

Top Losers

TickerCompanyCategory1W RtnYTD Rtn
NASATema Space Innovators ETFEquity-16.5%4.9%
SLViShares Silver TrustCommodity-13.6%-18.7%
RINGiShares MSCI Global Gold Miners ETFEquity-11.0%-11.7%
ETHAiShares Ethereum Trust ETFCryptocurrency-10.2%-47.7%
PALLETFS Physical Palladium SharesCommodity-9.2%-26.0%
FBTCFidelity Wise Origin Bitcoin FundCryptocurrency-7.9%-32.5%
IBITiShares Bitcoin Trust ETFCryptocurrency-7.8%-32.5%
MISLFirst Trust Indxx Aerospace & Defense...Equity-7.6%2.2%
PPLTETFS Physical Platinum SharesCommodity-7.5%-22.3%
ARKXARK Space & Defense Innovation ETFEquity-7.5%-8.5%

Top Gainers

TickerCompanyCategory1M RtnYTD Rtn
XBIState Street SPDR S&P Biotech ETFEquity13.7%24.3%
SOXXiShares Semiconductor ETFEquity9.7%107.7%
IHFiShares U.S. Healthcare Providers ETFEquity9.4%13.9%
IBBiShares Biotechnology ETFEquity8.4%8.9%
SOXQInvesco PHLX Semiconductor ETFEquity8.4%97.1%
MTUMiShares MSCI USA Momentum Factor ETFEquity8.0%35.7%
UNGUnited States Natural Gas Fund LPCommodity7.7%-4.2%
SPMOInvesco S&P 500 Momentum ETFEquity6.6%34.2%
KREState Street SPDR S&P Regional Bankin...Equity6.4%16.0%
SLYGState Street SPDR S&P 600 Small Cap G...Equity6.2%24.4%

Top Losers

TickerCompanyCategory1M RtnYTD Rtn
NASATema Space Innovators ETFEquity-36.5%4.9%
SLViShares Silver TrustCommodity-24.9%-18.7%
ETHAiShares Ethereum Trust ETFCryptocurrency-24.8%-47.7%
FBTCFidelity Wise Origin Bitcoin FundCryptocurrency-22.1%-32.5%
IBITiShares Bitcoin Trust ETFCryptocurrency-22.0%-32.5%
USOUnited States Oil Fund LPCommodity-20.2%58.1%
PPLTETFS Physical Platinum SharesCommodity-18.3%-22.3%
RINGiShares MSCI Global Gold Miners ETFEquity-15.7%-11.7%
PALLETFS Physical Palladium SharesCommodity-14.4%-26.0%
URAGlobal X Uranium ETFEquity-13.6%2.8%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Peers to compare with:

Financials

MNPRVRTXATYRAVLNCNXUCOAGMedian
NameMonopar .Vertex P.aTyr Pha.Avalyn P.Conexeu .Hemab Th. 
Mkt Price87.63480.180.5628.9810.2227.7228.35
Mkt Cap0.7122.0----61.4
Rev LTM012,218--0-0
Op Inc LTM-194,662---5--5
FCF LTM-103,710---4--4
FCF 3Y Avg-91,977----984
CFO LTM-104,241---4--4
CFO 3Y Avg-92,401----1,196

Growth & Margins

MNPRVRTXATYRAVLNCNXUCOAGMedian
NameMonopar .Vertex P.aTyr Pha.Avalyn P.Conexeu .Hemab Th. 
Rev Chg LTM-10.1%----10.1%
Rev Chg 3Y Avg-9.9%----9.9%
Rev Chg Q-7.8%----7.8%
QoQ Delta Rev Chg LTM-1.8%----1.8%
Op Inc Chg LTM-5.9%1,214.0%----604.0%
Op Inc Chg 3Y Avg-33.9%364.1%----165.1%
Op Mgn LTM-38.2%----38.2%
Op Mgn 3Y Avg-24.1%----24.1%
QoQ Delta Op Mgn LTM-0.2%----0.2%
CFO/Rev LTM-34.7%----34.7%
CFO/Rev 3Y Avg-21.5%----21.5%
FCF/Rev LTM-30.4%----30.4%
FCF/Rev 3Y Avg-17.7%----17.7%

Valuation

MNPRVRTXATYRAVLNCNXUCOAGMedian
NameMonopar .Vertex P.aTyr Pha.Avalyn P.Conexeu .Hemab Th. 
Mkt Cap0.7122.0----61.4
P/S-10.0----10.0
P/Op Inc-40.026.2-----6.9
P/EBIT-40.024.1-----7.9
P/E-49.928.1-----10.9
P/CFO-74.728.8-----23.0
Total Yield-2.0%3.6%----0.8%
Dividend Yield0.0%0.0%----0.0%
FCF Yield 3Y Avg-24.3%1.8%-----11.2%
D/E0.00.0----0.0
Net D/E-0.2-0.0-----0.1

Returns

MNPRVRTXATYRAVLNCNXUCOAGMedian
NameMonopar .Vertex P.aTyr Pha.Avalyn P.Conexeu .Hemab Th. 
1M Rtn39.9%10.2%15.6%8.5%-25.8%-0.4%9.3%
3M Rtn60.6%5.8%-29.4%-1.7%-29.0%-18.5%-10.1%
6M Rtn23.8%3.7%-24.2%-1.7%-29.0%-18.5%-10.1%
12M Rtn174.5%7.7%-89.0%-1.7%-29.0%-18.5%-10.1%
3Y Rtn1,937.4%38.2%-73.5%-1.7%-29.0%-18.5%-10.1%
1M Excs Rtn42.1%12.3%17.7%10.7%-23.6%1.7%11.5%
3M Excs Rtn42.3%-6.1%-41.6%-13.3%-40.6%-30.1%-21.7%
6M Excs Rtn16.6%-2.6%-29.9%-8.7%-36.0%-25.4%-17.1%
12M Excs Rtn142.4%-14.1%-110.2%-22.5%-49.8%-39.2%-30.9%
3Y Excs Rtn1,846.8%-27.5%-143.6%-69.4%-96.7%-86.1%-77.7%

Comparison Analyses

null

Financials

$ Mil | FY: 12/312026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q2
Period End3/31/202612/31/20259/30/20256/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/2023
Filing Date5/14/20263/27/202611/13/20258/12/20255/13/20253/31/202511/8/20248/9/20245/9/20243/28/202411/9/20238/10/2023
Key Financials Quarterly            
Total Revenue000000000000
Ebitda-5-6-4-3-3-11-2-2-2-2-2-2
Operating Income-5-6-4-3-3-11-2-2-2-2-2-2
Net Income-4-5-3-2-3-11-1-2-2-2-2-2
EPS-0.46-0.64-0.48-0.35-0.38-2.75-0.37-0.49-0.51-0.61-0.69-0.80
Key Financials TTM            
Total Revenue TTM000000000000
Ebitda TTM-19-17-22-19-18-16-7-7-8-9-10-10
Operating Income TTM-19-17-22-19-18-16-7-7-8-9-10-10
Net Income TTM-15-14-19-17-17-16-6-7-8-8-9-10
Growth Rates Quarterly            
Total Revenue Growth------------
EBITDA Growth-62.2%44.4%-159.9%-80.8%-86.9%-479.2%23.8%23.2%31.7%34.3%14.2%15.7%
Operating Income Growth-62.2%44.4%-159.9%-80.8%-86.9%-479.2%23.8%23.2%31.7%34.3%14.2%15.7%
Net Income Growth-48.3%52.4%-163.6%-43.0%-59.9%-502.3%33.2%22.0%32.6%37.4%18.6%20.4%
Margins Quarterly            
EBITDA Margin------------
Operating Income Margin------------
Net Income Margin------------
Cash & Debt            
Total Cash1371401445355606797810
Total Debt000000000000
Net Debt / (Cash)-137-140-144-53-55-60-6-7-9-7-8-10
Cash Flows Quarterly            
FCF from Operations-3-3-2-1-6-2-1-2-2-2-2-2
Cash Flows TTM            
FCF from Operations TTM-10-12-11-10-10-6-6-7-7-8-8-8
Returns to Shareholders Quarterly            
Dividends000000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly            
ROIC-22.9%-28.3%-19.9%-16.2%-16.6%-62.7%-9.9%-11.4%-11.4%-13.1%-14.6%-17.2%
Return on Invested Capital (ROIC) TTM            
ROIC TTM-20.5%-19.2%-26.3%-23.9%-22.8%-22.9%-11.0%-12.0%-13.3%-15.1%-17.4%-18.8%

Segment Financials

Assets by Segment
$ Mil20252024202320222021
Development of clinical and preclinical product candidates1416071321
Total1416071321


Price Behavior

Price Behavior
Market Price$87.63 
Market Cap ($ Bil)0.7 
First Trading Date12/19/2019 
Distance from 52W High-14.1% 
   50 Days200 Days
DMA Price$61.19$67.43
DMA Trendupup
Distance from DMA43.2%30.0%
 3M1YR
Volatility73.7%82.1%
Downside Capture24.93158.11
Upside Capture180.38242.80
Correlation (SPY)23.0%23.8%
MNPR Betas & Captures as of 5/31/2026

 1M2M3M6M1Y3Y
Beta5.453.622.111.811.861.66
Up Beta11.224.282.902.662.310.61
Down Beta0.57-1.36-0.08-0.040.871.22
Up Capture513%280%265%165%396%2895%
Bmk +ve Days13283667141432
Stock +ve Days11183059119355
Down Capture449%584%223%218%152%110%
Bmk -ve Days7132757109318
Stock -ve Days9223264128384

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with MNPR
MNPR149.6%82.0%1.47-
Sector ETF (XLV)17.9%15.1%0.8814.3%
Equity (SPY)22.1%12.4%1.3324.1%
Gold (GLD)20.8%27.7%0.679.9%
Commodities (DBC)23.3%18.5%0.99-11.9%
Real Estate (VNQ)11.6%13.8%0.5515.2%
Bitcoin (BTCUSD)-42.9%42.5%-1.2011.9%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with MNPR
MNPR22.8%296.0%0.55-
Sector ETF (XLV)6.2%14.8%0.231.3%
Equity (SPY)13.3%17.1%0.604.6%
Gold (GLD)17.4%18.3%0.773.7%
Commodities (DBC)7.9%19.5%0.30-0.5%
Real Estate (VNQ)2.8%18.9%0.052.4%
Bitcoin (BTCUSD)9.8%54.1%0.383.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with MNPR
MNPR-4.5%264.4%0.43-
Sector ETF (XLV)10.1%16.6%0.493.2%
Equity (SPY)15.3%18.0%0.735.4%
Gold (GLD)11.6%16.1%0.593.5%
Commodities (DBC)5.9%18.0%0.250.4%
Real Estate (VNQ)5.5%20.7%0.233.8%
Bitcoin (BTCUSD)56.4%66.5%0.973.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date6152026
Short Interest: Shares Quantity1.6 Mil
Short Interest: % Change Since 5312026-1.3%
Average Daily Volume0.1 Mil
Days-to-Cover Short Interest12.5 days
Basic Shares Quantity8.5 Mil
Short % of Basic Shares18.3%

Earnings Returns History

Updated 6/17/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
5/14/2026-2.8%2.8%0.8%
3/27/2026-1.5%-0.8%0.7%
11/13/20255.4%0.5%-9.0%
8/12/202514.6%9.3%36.9%
5/13/2025-3.6%5.1%-1.3%
11/8/20247.3%15.9%41.6%
8/9/2024-19.6%-13.8%-12.7%
5/9/2024-5.2%-20.3%8.1%
...
SUMMARY STATS   
# Positive888
# Negative131313
Median Positive2.2%6.9%14.1%
Median Negative-3.6%-13.5%-12.7%
Max Positive14.6%15.9%41.6%
Max Negative-24.8%-45.8%-54.9%
 Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
5/14/2026-2.8%2.8%0.8%
3/27/2026-1.5%-0.8%0.7%
11/13/20255.4%0.5%-9.0%
8/12/202514.6%9.3%36.9%
5/13/2025-3.6%5.1%-1.3%
11/8/20247.3%15.9%41.6%
8/9/2024-19.6%-13.8%-12.7%
5/9/2024-5.2%-20.3%8.1%
11/9/2023-3.0%-21.9%-6.6%
8/10/20233.2%-13.5%-20.4%
5/11/2023-6.6%-13.5%-6.0%
3/23/20230.6%-45.8%-54.9%
11/10/2022-24.8%-37.1%-42.4%
8/11/20220.3%-1.9%-4.7%
5/12/2022-8.0%9.5%14.4%
3/24/2022-1.1%2.3%-10.2%
11/12/2021-0.2%-3.0%-20.0%
8/12/20211.2%-0.6%13.7%
5/13/20211.2%8.7%19.4%
3/25/2021-6.4%-7.7%-12.8%
8/6/2020-2.8%-16.0%-27.2%
SUMMARY STATS   
# Positive888
# Negative131313
Median Positive2.2%6.9%14.1%
Median Negative-3.6%-13.5%-12.7%
Max Positive14.6%15.9%41.6%
Max Negative-24.8%-45.8%-54.9%

SEC Filings

Expand for More
Report DateFiling DateFiling
03/31/202605/14/202610-Q
12/31/202503/27/202610-K
09/30/202511/13/202510-Q
06/30/202508/12/202510-Q
03/31/202505/13/202510-Q
12/31/202403/31/202510-K
09/30/202411/08/202410-Q
06/30/202408/09/202410-Q
03/31/202405/09/202410-Q
12/31/202303/28/202410-K
09/30/202311/09/202310-Q
06/30/202308/10/202310-Q
03/31/202305/11/202310-Q
12/31/202203/23/202310-K
09/30/202211/10/202210-Q
06/30/202208/11/202210-Q
 Collapse to Preview
Report DateFiling DateFiling
03/31/202605/14/202610-Q
12/31/202503/27/202610-K
09/30/202511/13/202510-Q
06/30/202508/12/202510-Q
03/31/202505/13/202510-Q
12/31/202403/31/202510-K
09/30/202411/08/202410-Q
06/30/202408/09/202410-Q
03/31/202405/09/202410-Q
12/31/202303/28/202410-K
09/30/202311/09/202310-Q
06/30/202308/10/202310-Q
03/31/202305/11/202310-Q
12/31/202203/23/202310-K
09/30/202211/10/202210-Q
06/30/202208/11/202210-Q
03/31/202205/12/202210-Q
12/31/202103/24/202210-K
09/30/202111/12/202110-Q
06/30/202108/12/202110-Q
03/31/202105/13/202110-Q
12/31/202003/25/202110-K
09/30/202011/12/202010-Q
06/30/202008/06/202010-Q
03/31/202005/07/202010-Q
12/31/201903/27/202010-K
09/30/201912/19/2019424B4
06/30/201908/15/2019S-1

Recent Forward Guidance

Updated 6/1/2026

Latest: Q1 2026 Earnings Reported 5/14/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
2027 Cash Runway 2,028    

Prior: Q4 2025 Earnings Reported 3/27/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
2027 Cash Runway      

Insider Activity

Updated 4/26/2026
Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value		Value of
Held Shares		Form
1Vu, Quan AnhChief Financial OfficerDirectBuy1229202569.951,500104,925104,925Form
2Klausner, Arthur J DirectSell1219202567.155,121343,889588,392Form
3Tactic, Pharma LlcChief Executive OfficerDirectSell926202563.61550,22934,999,95717,303,519Form
4Tsuchimoto, Kim R DirectSell716202540.008,904356,171459,454Form
5Starr, Christopher M DirectSell716202540.0016,800672,020206,926Form
 Collapse to Preview
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value		Value of
Held Shares		Form
1Vu, Quan AnhChief Financial OfficerDirectBuy1229202569.951,500104,925104,925Form
2Klausner, Arthur J DirectSell1219202567.155,121343,889588,392Form
3Tactic, Pharma LlcChief Executive OfficerDirectSell926202563.61550,22934,999,95717,303,519Form
4Tsuchimoto, Kim R DirectSell716202540.008,904356,171459,454Form
5Starr, Christopher M DirectSell716202540.0016,800672,020206,926Form
6Robinson, ChandlerChief Executive OfficerDirectSell716202540.0016,800672,0202,938,968Form
7Tactic, Pharma LlcChief Executive OfficerDirectSell404202535.0033,3341,166,69028,778,925Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 6/25/2026